AML19

• Research type

  Research Study

• Full title

  Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome (AML19)

• IRAS ID

  154468

• Contact name

  Nigel Russell

• Contact email

  nigel.russell@nottingham.ac.uk

• Sponsor organisation

  Cardiff University

• Eudract number

  2014-002195-90

• Clinicaltrials.gov Identifier

  C26822/A16484, Award Ref. Number

• Research summary

  AML19 will build upon the results of previous trials in acute myeloid leukaemia. It will evaluate several relevant therapeutic questions in patients who are 18­60 years old and suitable for intensive chemotherapy. For patients who do not have the APL subtype, the investigators will evaluate the best way of adding mylotarg to induction chemotherapy. After induction, patients will be characterised based upon their prognosis and may enter different randomisations ­ the randomisations allow patients to access different treatments based on their disease profile. The investigators will also evaluate whether continued monitoring of patients can improve outcomes and affects quality of life. Patients with the APL subtype will enter a different part of the trial.

• REC name

  Wales REC 3

• REC reference

  14/WA/1056

• Date of REC Opinion

  12 Aug 2014

• REC opinion

  Further Information Favourable Opinion